[P-phenomenon in progressive chronic polyarthritis].
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000276:immunology*; D002738:Chloroquine / Q000627:therapeutic use; D003348:Cortisone / Q000627:therapeutic use; D006046:Gold / Q000627:therapeutic use; D006073:Gout / Q000276:immunology; D007128:Immunoglobulin Fragments / Q000032:analysis*; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007213:Indomethacin / Q000627:therapeutic use; D010003:Osteoarthritis / Q000276:immunology; D011720:Pyrazoles / Q000627:therapeutic use; D051381:Rats; D013167:Spondylitis, Ankylosing / Q000276:immunology; D013582:Synovial Fluid / Q000032:analysis; D014394:Tuberculosis, Osteoarticular / Q000276:immunology
D000970:Antineoplastic Agents; D007128:Immunoglobulin Fragments; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; D011720:Pyrazoles; D006046:Gold; D002738:Chloroquine; D003348:Cortisone; D007213:Indomethacin
Untersuchungen zum P-Phänomen bei progressiv chronischer Polyarthritis.